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Abstract 
Purpose: To produce truncated recombinant form of tumor necrosis factor receptor 1 (TNFR1), 
cysteine-rich domain 2 (CRD2) and CRD3 regions of the receptor were generated using pET28a and E. 
coli/BL21. 
Methods: DNA coding sequence of CRD2 and CRD3 was cloned into pET28a vector and the 
corresponding protein was expressed under induction of isopropyl β-D-1-thiogalactopyranoside (IPTG) 
as 6×His tagged using E.coli BL21 (DE3) expression system. The protein was then purified by Ni-NTA 
affinity chromatography. The fragment insertion, expression of recombinant protein and the yield of 
expression were evaluated. 
Results: Protein expression was achieved by identifying a band with molecular weight of 1488.3 Da. 
The recombinant protein of CRD2 and CRD3 was most efficiently expressed in 0.5 mM IPTG and 3 h of 
incubation at 37 °C with high yield equal to 0.3 µg/µl. Also, the highest concentration of imidazole for 
purification of the recombinant protein was 250 mM. 
Conclusion: A truncated form of TNFR-1 has been successfully expressed in a bacterial expression 
system and purified on affinity column. The purified protein can be used in in vivo experiments to 
prepare specified agonist antibodies for TNFR-1.  
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Tumor necrosis factor-α (TNF-α) is a multi-
functional cytokine with various roles in 
inflammation, immunity, cell proliferation, 
differentiation and apoptosis [1]. TNF-α exists in 
two forms: transmembrane and soluble which 
exert their effects through binding and activating 
two TNF family receptors: TNF receptor 1 
(TNFR1) and TNF Receptor 2 (TNFR2) [2]. Many 
studies have been conducted on antitumor 
functions of the receptors [3]. The major 
difference between the two receptors has been 
reported to be the presence of a death domain in 
TNFR1 and absence of a death domain in 
TNFR2 [4]. TNF has been found to activate 
proapoptotic signaling cascade through TNFR1 
[5] which is expressed in various types of cells, 
tissues [6] and tumors [7]. Studies have shown 
that antibodies against TNFR1 mimic the effect 
of TNF-α [8,9] and as a result initiate the 
apoptosis process. The extracellular region of the 
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receptor consists of four cysteine-rich domains 
(CRDs): CRD1, CRD2, CRD3, CRD4. CRD2 and 
CRD3 play important roles in ligand binding [10]. 
TNF-α binding to TNFR1 induces receptor 
trimerization and recruitment of various signaling 
proteins. TNFR1 transduces apoptotic and anti-
inflammatory signals via the employment of FAS-
associated death domain protein (FADD) and 
further recruitment of caspase-8. Activated 
caspase-8 triggers a proteolytic cascade that 
entangles caspases-3, -6 and -7, eventually 
inducing apoptosis. Also TNFR-1 mediates anti-
apoptotic and inflammatory responses like 
activation of the necrosis factor (NF)-κB by 
employing TNF-receptor-associated factor 2 
(TRAF2) and receptor-interacting protein 1 
(RIP1) [11]. Therefore, inhibition of NF-κB activity 
enhances TNF-α-induced cell death while an 
increase in NF-κB activity protects the cells from 
TNF-α-induced death [12]. 
 
In this study, CRD2 and CRD3 regions in a pET 
vector were cloned using E.coli/BL21 and 
expressed. Various techniques including agarose 
gel electrophoresis, sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE), 
western blot, Ni-NTA chromatography, dialysis 






Diaminobenzidine (DAB) was purchased from 
Sigma Company (USA). Acrylamide, sodium 
dodecyl sulfate and agarose were obtained from 
Merck Company (Germany). Original pET28a 
and recombinant pET28a plasmid were gifted 
and E.coli/BL21 was prepared from Pasteur 
Institute of Iran, Tehran. BamHI, Sal I, restriction 
enzymes and T4 DNA Ligase were purchased 
from Fermentas Company (Finland). DNA 
extraction kit and Ni-NTA agarose resin were 
obtained from Bioneer Company (South Korea) 
and Qiagen Company (Germany), respectively. 
Distilled water was used throughout the 
experiment. All materials were of analytical 
grade. 
 
Cloning of CRD2 and CRD3 
 
Recombinant pET28a plasmid resistance to 
kanamycin, containing CRD1, CRD2, CRD3 and 
CRD4 was transferred into susceptible bacteria 
(E.coli/BL21) by chloride calcium and heat shock 
methods. For this purpose, cultured bacteria in 
the log phase (OD=0.4) were centrifuged (9000 
rpm, 3 min) and sediment was obtained. The 
sediment was mixed with 1 mL 0.1M cold 
calcium chloride, and placed on ice for 30 min 
and then centrifuged. The supernatant was then 
discarded and the process was repeated. The 
suspension of bacteria was then incubated with 
recombinant vector (1.5 µl, 60 ng/µl) on ice for 30 
min. The mixture was shocked with temperature 
(42 oC, 90s) and placed on ice for 2 min, followed 
by culturing into 1 ml liquid LB culture medium in 
37 oC.  
 
After 1 h, 500 µL of medium was taken and 
cultured on the plate of LB medium containing 
kanamycin (37 oC, 18 h). The recombinant 
plasmid was extracted and the fragment 
containing CRD2 and CRD3 was obtained using 
BamH1 and SA1 I restriction enzymes. Next, the 
fragment was run on agarose gel electrophoresis 
and then obtained using DNA extraction kit. It 
was then inserted into original pET28a plasmid 
after excision of vector by BamH1 and SA1 I 
restriction enzymes. The fragment was ligated to 
vector using T4 DNA ligase and transferred into 
susceptible bacteria. To verify the insertion of 
fragment into plasmid, the plasmid was extracted 
and digested by the two restriction enzymes and 
run on agarose gel electrophoresis. 
 
Induction of protein expression 
 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
was used to induce the expression of 
recombinant protein. In pET28a vector, T7 
promoter is responsible for the transcription of 
the inserted fragment. Although recombinant 
bacteria were cultured in liquid LB culture 
medium containing kanamycin in a shaker 
incubator (37 oC, 180 rpm). After 3 h, various 
concentrations of IPTG were added to the 
medium. In various time intervals of 2, 3 and 4 h 
after induction by IPTG, sampling was 
performed. The total protein was extracted by 
sonication on ice [13]. In addition, western 
blotting technique was used to detect the 
expression of recombinant protein. 
 
Scale up of recombinant protein 
 
The recombinant protein was produced on a 
large scale using one-liter Erlenmeyer flask and 
shaker incubator (37 oC, 180 rpm). Ni-NTA 
affinity chromatography technique was used to 
purify the protein. Bradford method was used to 




The data were statistically analyzed by one-way 
analysis of variance (ANOVA) using IBM 
Statistics SPSS software version 19, and 
statistical significance was set at p < 0.05. The 
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results are expressed as mean ± standard 




Cloning of CRD2 and CRD3 
 
Evaluating the growth of recombinant bacteria 
containing CRD1, CRD2, CRD3 and CRD4 
confirmed bacterial transformation (i.e. growth of 
antibiotic-resistance versus no growth of 
antibiotic-sensitive). Also, the insertion of the 
regions into plasmid was confirmed by agarose 




Figure 1: Agarose gel electrophoresis of original (left 
column) and recombinant vector (right column). The 
difference in the movement between two plasmids 
confirmed the insertion of fragment containing CRD1, 
CRD2, CRD3 and CRD4 into vector. 
 
In addition, bacterial transformation with 
recombinant plasmid containing CRD2 and 
CRD3 was confirmed. For this purpose, plasmid 
extraction was performed and excised by BamH1 
and SA1 I restriction enzymes and then run on 
agarose gel electrophoresis. The fragment 
related to CRD2 and CRD3 was demonstrated 




Figure 2: Agarose gel electrophoresis of DNA 
fragment containing CRD2 and CRD3 with 264 bp 
(columns 1 and 2) 
 
Induction of protein expression 
 
The recombinant protein was successfully 




Figure 3: Western blot technique to confirm the 
expression of recombinant protein. 1) protein marker, 
2) the expressed recombinant protein after induction 
by IPTG, and 3) the expressed recombinant protein 
before induction by IPTG 
 
In addition, the optimum condition for protein 
production was 3 h incubation with 0.5 mM IPTG. 
 
To extract the recombinant proteins from bacteria 
cultured in erlenmeyer flasks, 8 M urea and 
sonication (Bandelin Sonopuls HD 2070, 
Bandelin Elec., Germany) (3 min, 50 W) were 
used and the samples were run on SDS-PAGE  
(Figure 4). 
 
To purify the protein, Ni-NTA affinity 
chromatography was performed using a gradient 
of imidazole concentration. It was found that an 
elution buffer with concentration of 250 mM of 
imidazole was the most appropriate buffer for 
protein purification (Figure 5). 
 
In addition, to purify the recombinant protein from 
urea and salt impurities, dialysis membrane (Cut 
off 2000 Da, Sigma) was used and the protein 
was run on SDS-PAGE (Figure 6). 
 
Finally, evaluating the concentration of the 
recombinant protein by Bradford technique 
confirmed high yield production equal to 0.3 
µg/µL. 
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Figure 4:  SDS-PAGE of extracted recombinant proteins from four Erlenmeyer flasks. Columns 1 to 8 show the 
proteins after induction by various concentrations of IPTG in different time intervals. Columns 1 to 3 show target 
proteins after 4 h induction with 0.25, 0.5 and 1 mM of IPTG, respectively. Columns 4 and 5 demonstrate the 
target proteins after 3 h induction with 0.25 and 0.5 mM of IPTG, respectively. Columns 6 to 8 display the 
proteins after 2 h induction with 0.25, 0.5 mM and 1 mM of IPTG, respectively. Column 9 presents proteins before 




Figure 5: SDS-PAGE of purified recombinant proteins. An elution buffer was used with various concentrations of 
imidazole. The columns show the expressed protein of CRD2 and CRD3 regions extracted by various 
concentrations of imidazole solution. The protein shown in columns 1, 2 and 3 is extracted with 50 mM imidazole. 
Columns 4, 5 and 7 present the protein extracted with 100 mM imidazole. Columns 8 and 9 show the extracted 
protein with 150 mM imidazole and columns 10-15 present extracted protein with 250 mM imidazole. Column 6 
shows the marker protein. Columns 16 and 17 are the recombinant proteins extracted twice with 0.5 ml of 250 





Figure 6: SDS-PAGE of the recombinant protein 
extracted by Ni-NTA chromatography before dialysis 




There are different reports on the association 
between TNF protein family and human 
disorders such as cancers, immunogenic 
diseases, cardiovascular, nervous system, lung 
and metabolic disorders [4]. TNF-α induces cell 
apoptosis through binding to its receptor TNFR-1 
[5]. Various studies have confirmed the tumor 
suppressive effects of TNFR-1 [3,14]. These 
effects can be induced by agonistic antibodies 
specific for TNFR-1 [15]. Therefore, in this study 
we aimed to construct recombinant protein of 
CRD2 and CRD3 for the preparation of a specific 
antibody against TNFR-1. Antibodies specific for 
TNFR1 can be obtained through antigenic 
properties of receptor. 
 
It has been demonstrated that two domains of 
TNFR-1, including CRD2 and CRD3, play a vital 
role in binding to ligands [10]. DNA coding 
sequence for the domains was then inserted into 
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pET28a plasmid and transferred into competent 
bacteria E. coli/BL21. E. coli was chosen 
because of its appropriate properties for 
recombinant protein production such as rapid 
growth in simple and cheap media, well-known 
genetic information, availability of various types 
of vectors including cloning and expressing 
vectors, easy control and possibility of high 
recombinant protein production [16]. Evaluating 
the growth of bacteria in culture medium 
confirmed bacteria transformation. Also, the 
construction of plasmid containing CRD2 and 
CRD3 regions was shown by plasmid extraction 
and excision with BamH1 and SaI 1 enzymes 
and their appearance on the agarose gel 
electrophoresis.  
 
In addition, the construction of the plasmid, 
containing CDR2 and CDR3 was reported by 
Jian et al [17]. They ligated the fragments to 
pGEX-3 X plasmid, transferred it into E. coli 
DH5α, and expressed it under induction of 0.25 
mM IPTG [17]. Furthermore, scale up of 
recombinant protein production was 




The recombinant protein of CRD2 and CRD3 
regions of TNFR1 which can be used for the 
production of their specific antibodies was 
successfully produced. It has been observed to 
stimulate the expressed TNFR1 in cancer cells 
as well as triggers apoptotic pathways. In 
addition, it has been found the pET28a plasmid 
and E. coli/BL21 are appropriate for the 
production of recombinant protein, containing 
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